Fact checked by Nick Blackmer Novo Nordisk launched a direct-to-consumer program last week to sell Wegovy at a reduced price ...
Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.
The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
The weight-loss drug can cost patients more than $1,000 a month if they do not have health insurance coverage.
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...
The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...
After years of calling obesity drug stocks overhyped, a top analyst now sees Novo Nordisk as a big opportunity.